Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3377166 | 0.82 | ALDH1A1 (0.43) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3378815 | 0.81 | MEN1 (0.41) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL4643810 | 0.80 | ALDH1A1 (0.41) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3377782 | 0.80 | MEN1 (0.46) | MEN1KMT2AGRIN1GRIN2BBCHE | |
| SCHEMBL3377784 | 0.80 | MEN1 (0.46) | MEN1KMT2AGRIN1GRIN2BBCHE | |
| SCHEMBL4643805 | 0.79 | CXCR4 (0.39) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3375004 | 0.78 | ALDH1A1 (0.39) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3377162 | 0.78 | ALDH1A1 (0.39) | MEN1KMT2AGRIN1GRIN2B | |
| SCHEMBL3442154 | 0.78 | HRH3 (0.36) | CHRM4ACHECCR3 | |
| SCHEMBL3378811 | 0.78 | ALDH1A1 (0.36) | MEN1KMT2AGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | MEN1 2959/4885KMT2A 1261/4885CHRM4 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.